We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Months after President Donald Trump rolled out his administration’s drug pricing “blueprint,” wheels are in motion in Washington, D.C., as legislators and the federal government work to implement proposals pushing more transparency.